<DOC>
	<DOCNO>NCT01290380</DOCNO>
	<brief_summary>The purpose study evaluate potential inhibitory effect ASA404 CYP1A2 , CYP2C9 , CYP3A4 CYP2C19 mediate metabolism respective probe drug caffeine , diclofenac , simvastatin , omeprazole , respectively . This accomplish simultaneous administration four substrate part cocktail order characterize potential in-vivo drug-drug interaction . This cocktail approach propose per FDA guidance screen tool potential in-vivo drug-drug interaction Compared individual administration specific probe multiple study , simultaneous administration multiple in-vivo probe drug-metabolizing enzyme offer several distinct advantage minimize confound influence inter-individual intra-individual variability time . Substrates CYP enzyme choose base FDA guidance recommendation take account 1 . The substrate specific individual CYP enzyme , 2 . There interaction among substrate ; 3 . The study conduct sufficient number subject .</brief_summary>
	<brief_title>A Study Evaluate Effects ASA404 Alone Combination With Taxane-based Chemotherapies Pharmacokinetics Drugs Patients With Advanced Solid Tumor Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Vadimezan</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Histologicallyproven radiologicallyconfirmed diagnosis advance metastatic solid tumor treatment investigational agent alone combination docetaxel placlitaxel +carboplatin appropriate ; Body Mass Index ( BMI ) must within range 1830 ; A minimum 4 week must elapse since last treatment cancer therapy , ( i.e . endocrine therapy , immunotherapy , chemotherapy , ect ) ; Willing able remain clinic least 2 day ( night dose night dose 24 hour ) 3 x 's receive cocktail ( Day 1 , Day 8 Day 15 Patients CNS metastasis . ( Patients clinical sign CNS metastases must CT MRI brain perform rule CNS metastasis order eligible study participation . Patients brain metastasis surgically remove irradiated active residual disease confirm image allow ) Patients recover acute radiotherapyrelated toxicity ; Prior exposure Vascular Disrupting Agents ( VDAs ) vascular target agent Right bundle branch block ( RBBB ) , complete leave bundle branch block ( LBBB ) , bifascicular block ( right bundle branch block either leave anterior hemiblock leave posterior hemiblock ) Concomitant use drug risk QT prolongation and/or cause torsade de point If patient treat paclitaxel : Known allergy hypersensitivity platinumcontaining drug , taxanes , drug formulate Cremophor EL ( polyoxyethylated castor oil ) known excipients drug Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction take paclitaxel therefore consider effective contraceptive method study use single agent . Patients take oral , implantable , injectable contraceptive willing otherwise unable use concomitant barrier method exclude . The Investigator shall counsel patient accordingly . For list substrate human liver microsomal P450 enzyme , visit website ( http : //medicine.iupui.edu/flockhart/ ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Solid tumor malignancy ,</keyword>
	<keyword>simvastatin ,</keyword>
	<keyword>caffeine ,</keyword>
	<keyword>omeprazole diclofenac ,</keyword>
	<keyword>ASA404 ,</keyword>
	<keyword>PK data</keyword>
</DOC>